<DOC>
	<DOCNO>NCT02339129</DOCNO>
	<brief_summary>This Phase 2 , prospective , randomize , dual-center , double-blind , placebo-controlled , parallel-group study design determine dosing interval , efficacy safety SST-0225 ( 5.4 gram , apply 6 time 24 hour , 48-hour dosing period ) treatment pain associate DOMS .</brief_summary>
	<brief_title>Dosing Interval Study SST-0225 Topical Ibuprofen Cream Treatment Delayed Onset Muscle Soreness</brief_title>
	<detailed_description>This Phase 2 , prospective , randomize , dual-center , double-blind , placebo-controlled , parallel-group study design determine dosing interval , efficacy safety SST-0225 ( 5.4 gram , apply 6 time 24 hour , 48-hour dosing period ) treatment pain associate DOMS . As part screen process , even Day -2 , eligible subject undergo exercise regimen design induce DOMS elbow flexor non-dominant arm ( see Section 11 ) . 36 ( ±2 ) hour follow exercise regimen , subject return clinic evaluate eligibility active treatment phase study . Eligible subject experience sufficient level pain 36 ( ± 2 ) hour exercise randomize receive either SST-0225 placebo . For first 24 hour dose period , subject remain clinic ( on-site ) . Subjects apply first dose Investigational Product ( IP ) randomization ( 0 hour ) second dose upon request ( PRN need ) . All subsequent dos apply every 5 ( ±1 ) hour . The total number dose shall exceed 6 first 24 hour period . Subjects also allow take rescue medication first 24 hour dose period . Subjects complete Visual Analog Scale ( VAS ) pain/soreness movement assessment follow time point on-site first 24 hour : 0 ( prior first dose IP ) , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 16 , 24 hour post first dose IP immediately prior second dose IP . All assessment must complete unless subject asleep . Subjects restrict maximum 8 hour sleep order limit number miss VAS pain/soreness movement assessment due sleep . Immediately upon waken Day 2 , subject instruct apply dose IP unless less 5 ( ±1 ) hour since last dose IP . After subject complete 24 hour VAS pain/soreness movement assessment , release clinic continue outpatient treatment second 24 hour dose period . During second 24 hour dose period ( 24-48 hour post first dose IP ) , subject away clinic ( off-site ) apply IP every 5 ( ±1 ) hour . The total number dose shall exceed 6 dos second 24 hour period . Rescue medication make available subject second 24 hour period . During second 24 hour period , subject complete VAS pain/soreness movement assessment prior IP dose 1 hour post dose IP . Refer Schedule Evaluations Appendix A ( on-site evaluation ) Appendix B ( off-site evaluation ) detail regard timing study procedure .</detailed_description>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy male female subject 16 65 year age .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>